Repligen gets fast tracked for spinal muscular atrophy

Waltham, MA-based biotech Repligen has received FDA fast-track designation for its spinal muscular atrophy treatment, RG3039. The drug also received orphan drug status from the EMA. Repligen is preparing for its first Phase I trial of the drug. Repligen release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.